Immunotherapeutic strategies have had a profound impact on cancer patient outcome. As such, targeting the immune checkpoints in particular has gained widespread acceptance as a viable immune therapy for several malignancies. Despite the success of immune checkpoint inhibitors in extending the survival of patients with melanoma or lung cancer, the use of checkpoint blockade in the treatment of glioma is far from established. The goal of this review is to outline the current data on the use of checkpoint inhibition for the treatment of glioma, with additional emphasis on oligodendroglioma.
|Original language||English (US)|
|Title of host publication||Oligodendroglioma|
|Subtitle of host publication||Clinical Presentation, Pathology, Molecular Biology, Imaging, and Treatment|
|Number of pages||10|
|State||Published - Jan 1 2019|
ASJC Scopus subject areas